Aristides Capital’s ImmunityBio IBRX Stock Holding History

Aristides Capital’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-20,000	Closed	-$246K	–	104
2020 Q2	$246K	Buy	+20,000	New	+$113K	0.19%	73

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Aristides Capital's IBRX Position: Q3 2020 in Review

Aristides Capital sold out of ImmunityBio (IBRX) in Q3 2020, closing a stake of 20,000 shares — an estimated $246K sold.

Aristides Capital first reported a position in IBRX in Q2 2020 and held it in 1 quarter. The position peaked at $246K in Q2 2020. 95 funds tracked by Wall St. Rank hold IBRX as of Q3 2020.

Aristides Capital reported no remaining ImmunityBio position as of Q3 2020 after selling out during the quarter.
Aristides Capital sold 20,000 ImmunityBio shares in Q3 2020, an estimated $246K.
Aristides Capital first reported a position in ImmunityBio in Q2 2020 and held it in 1 quarter.
Aristides Capital's ImmunityBio position peaked at $246K in Q2 2020.
95 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2020.

Based on Aristides Capital's 13F filing for Q3 2020, filed 12 Nov 2020.